AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Omeros Corporation
Video analysis: OMER
All videosNo video analysis for this stock yet. Request one from our team.
News: OMER
BlackRock Inc. Invests $57.48 Million in Omeros Corporation $OMER
BlackRock Inc. purchased a new stake in Omeros Corporation (NASDAQ: OMER) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 6,044,633 shares of the biopharmaceutical company's stock, valued at approximately $57,484,000. BlackRock Inc. owned approximately 8.35% of Omeros at the end
What Makes Omeros (OMER) a Strong Momentum Stock: Buy Now?
Does Omeros (OMER) have what it takes to be a top stock pick for momentum investors? Let's find out.
Omeros (OMER) Just Flashed Golden Cross Signal: Do You Buy?
Omeros Corporation (OMER) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, OMER's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross.
Omeros Corporation (NASDAQ:OMER) Receives Consensus Recommendation of “Moderate Buy” from Brokerages
Shares of Omeros Corporation (NASDAQ: OMER - Get Free Report) have been given an average recommendation of "Moderate Buy" by the six analysts that are covering the company, Marketbeat.com reports. Three analysts have rated the stock with a hold recommendation, two have issued a buy recommendation and one has issued a strong buy recommendation on the
Omeros Corporation (OMER) Q2 2026 Earnings Call Transcript
Omeros Corporation (OMER) Q2 2026 Earnings Call Transcript
Omeros Q2 Earnings Call Highlights
Omeros NASDAQ: OMER reported second-quarter net sales of $28.5 million for YARTEMLEA, its newly launched treatment for hematopoietic stem cell transplant-associated thrombotic microangiopathy, or TA-TMA, as the company generated positive operating cash flow and reduced its convertible debt after the quarter ended.
Omeros (OMER) Q2 Earnings and Revenues Beat Estimates
Omeros (OMER) came out with quarterly earnings of $0.02 per share, beating the Zacks Consensus Estimate of a loss of $0.27 per share. This compares to a loss of $0.53 per share a year ago.
Omeros Corporation Reports Second Quarter 2026 Financial Results
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the second quarter ended June 30, 2026, which include: Second Quarter and Recent Highlights YARTEMLEA®, the first and only approved treatment for stem cell transplant-associated thrombotic microangiopathy (TA-TMA), an often-lethal complication of stem cell transplantation, generated gross revenues of $32.2 million in the second quarter of 2026, an incre.
Similar companies
-
ADC Therapeutics S.A.
ADCT
·
New York Stock Exchange
Compare
-
Neumora Therapeutics, Inc. Common Stock
NMRA
·
NASDAQ
Compare
-
Lexicon Pharmaceuticals, Inc.
LXRX
·
NASDAQ
Compare
-
Bicycle Therapeutics plc
BCYC
·
NASDAQ
Compare
-
4D Molecular Therapeutics, Inc.
FDMT
·
NASDAQ
Compare
-
Fulcrum Therapeutics, Inc.
FULC
·
NASDAQ
Compare